Lesinurad
 | |
 | |
| Systematic (IUPAC) name | |
|---|---|
|
2-{[5-Bromo-4-(4-cyclopropyl-1-naphthyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid | |
| Clinical data | |
| Trade names | Zurampic |
| AHFS/Drugs.com | entry |
| Routes of administration | Oral (tablets) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~100%[1] |
| Protein binding | >98% |
| Metabolism | Hepatic (CYP2C9) |
| Biological half-life | ~5 hours |
| Excretion | Urine (63%), feces (32%) |
| Identifiers | |
| CAS Number | 878672-00-5 |
| ATC code | M04AB05 (WHO) |
| PubChem | CID 56928182 |
| ChemSpider | 28527877 |
| KEGG | D09921 |
| ChEBI |
CHEBI:90929  |
| Chemical data | |
| Formula | C17H14BrN3O2S |
| Molar mass | 404.28 g·mol−1 |
| |
| |
Lesinurad (brand name Zurampic, zer-AM-pik) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.[1] It received FDA approval on December 22, 2015.[2][3] The European Commission granted a marketing authorisation valid throughout the European Union on 18 February 2016.[4]
References
- 1 2 "Zurampic (lesinurad) Tablets, for Oral Use. Full Prescribing Information" (PDF). AstraZeneca AB, S-151 85 Sodertalje, Sweden. Retrieved 23 December 2015.
- ↑ "FDA Approves Zurampic for Patients With Gout". Medscape. Dec 22, 2015.
- ↑ "FDA approves Zurampic to treat high blood uric acid levels associated with gout". Food and Drug Administration. December 22, 2015.
- ↑ "EPAR summary for the public" (PDF). EMA. Mar 13, 2016.
| ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, March 13, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.